Engineered organism debate

H1: prepare an ethical position without personal records

Today you evaluate an original paper proposal about engineered bacteria making a medicine. You do not build, handle or release an organism. No patient or student records are involved.

The final product is one sentence giving your position and a specific containment or patient-benefit reason. Keep your two reasons, debate notes and safeguards reflection as supporting work.

Warmup: use E1 to name a medicine made with living cells. Explain what losing that production option could mean for access to a treatment. Do not predict an individual outcome.

Then name one possible concern when scientists change bacterial genes. Treat it as a concern to assess, not a measured failure in D1.

For the three-medicine prerequisite, use all three E1 examples. Record the production cell type supplied for each. Do not list medicines you or relatives have taken.

A factory is a production setting; living cells can be part of its process. These are not opposite categories. E1 supplies examples, not the current global share of insulin production.

The earlier product lesson taught that a claim needs evidence and honest status. Apply that rule here even if your April 29 product remains unfinished.

E1: three real production examples and their limits

FDA records that Humulin became the first approved biosynthetic human insulin in 1982. Its history describes recombinant production using bacteria as an alternative to dependence on animal glands. [FDA-INSULIN]

Insulin is used in diabetes treatment. Losing a production option could limit treatment supply, but this history does not establish a current shortage or anyone’s clinical outcome. [FDA-INSULIN]

Example two: the GENOTROPIN label describes somatropin, a human growth hormone protein, made by recombinant DNA technology in Escherichia coli bacteria. [LABEL-GH]

Example three: the EPOGEN label describes epoetin alfa made by mammalian cells carrying genetic instructions for human erythropoietin. These are mammalian production cells, not bacteria. [LABEL-EPO]

All three examples use living cells in medicine manufacture. They do not show that every medicine is made this way. A production cell is not the same thing as the finished medicine.

These sources establish examples of production. They supply no prices, clinic budgets, local availability or numerical escape rates. Do not promise that engineering alone makes medicine affordable.

Use medicine names and production facts only. This lesson gives no recommendation to take, stop or change a medicine.

E2: what genetic engineering means here

Genetic engineering changes an organism’s DNA using laboratory methods. Recombinant DNA can combine DNA segments, and cells can copy the resulting DNA. NHGRI describes insulin and growth hormone applications. [NHGRI-GE] [NHGRI-RDNA]

DNA carries genetic information. A gene is a DNA region with information used to make a functional product. A protein is a molecule made from amino-acid building blocks.

MedlinePlus describes genome editing as changing DNA at particular locations. CRISPR-Cas9 is one approach. Do not assume every engineered organism was made by that approach. [MEDLINE-EDIT]

For this debate, the bacterium is a proposed production organism. The intended product is insulin medicine. The proposal does not call for giving people live bacteria or releasing them outdoors.

A selectable marker helps identify cells with a linked genetic feature. That identification role is different from preventing escape or harm. A marker alone does not demonstrate containment. [MARKER]

You need these meanings to assess the proposal. No genetic sequence, construction method, organism selection or operating conditions are supplied or requested.

D1: complete original paper proposal

Fictional proposal: a manufacturer seeks ethical support in principle for contained production of insulin using engineered Escherichia coli bacteria. This is an invented review case, not an actual facility or local clinic plan.

The stated aim is to provide another production option for an established medicine. No claim is made that the proposed facility has produced a safe medicine or lowered anyone’s price.

The proposal promises a qualified safety review before work, trained personnel, restricted access and a documented response to failures. These are proposed safeguards, not verified performances.

No actual strain assessment, facility inspection, product-quality results, environmental monitoring, worker exposure data or patient access plan is supplied. No escape probability can be calculated from this case.

The reviewers must consider patients, workers and nearby communities. Patients could value reliable supply. Workers could carry exposure burdens. Communities could reasonably ask who monitors failures and reports them.

These stakeholder concerns are original prompts, not interviews or claims that every person agrees. No actual illness, accident or escape has occurred in the case.

Your choice may be conditional support, postponement pending evidence or a reasoned objection. State what your position allows and what it does not. No classroom vote authorizes real production.

E3: risk assessment and accountable safeguards

CDC and NIH describe the BMBL as advisory biosafety guidance, not a regulation. Its core is risk assessment matched to the work; one document cannot cover every risk combination. [BMBL]

Distinguish a hazard, a possible source of harm, from risk, which concerns likelihood and consequences in stated conditions. Severity asks how serious a harm could be.

An escape is not itself a complete health outcome. Survival, exposure and the organism’s properties matter. D1 provides none of the measurements needed to infer those outcomes.

For D1, ask for evidence that proposed safeguards fit the actual work and are checked. Name who reviews concerns, who may stop work and how affected people can raise questions.

You can request a documented independent safety review and a clear stop-and-review rule after a reported failure. These are high-level governance proposals, not a laboratory protocol or legal finding.

An assigned containment level must follow qualified assessment, not a classroom guess. A promise, a selection marker or a checked box does not establish zero risk.

Keep patient benefit, likelihood, severity and fairness separate in your reasoning. Missing evidence may justify waiting without claiming harm is certain. A known benefit does not remove the need for review.

C1: complete opposing positions and solo rounds

Position A, conditional support: The insulin history supports the value of a production option. I support the idea only if qualified review verifies suitable safeguards and product quality before work proceeds.

A also asks for a patient access plan and clear responsibility for reporting failures. Its strongest point is preserving potential benefit while imposing conditions. Those conditions are not yet met in D1.

Position B, postpone approval: Patients matter, but D1 lacks the evidence needed to judge exposure burdens and safeguard performance. I would wait for the safety review and access plan.

B would reconsider if those records address its concerns. Its strongest point is refusing to shift unknown burdens onto others. Its cost is delay in a possible production option.

Both positions use the same D1 facts. Neither asserts an actual shortage, price saving, accident or measured risk. You may defend either with clear conditions and evidence limits.

Group round one: state one patient-benefit reason and one safety reason. Track the speaker’s claim, cited card, uncertainty and proposed oversight. Record actual words or a fair paraphrase.

Group round two: reply to the strongest opposing concern and name the safeguard or missing evidence that matters. Record what changed in your view, or explain why it did not.

If no group is available, complete both rounds using A and B. Label the speakers supplied positions and your replies solo practice. Do not invent a classmate, discussion or class vote.

For the debrief, name the concern hardest to dismiss and explain its remaining limit. For the extension, steelman the opposition and state one piece of evidence that would change your vote.

Q1: self-check and conceptual preparation

Self-check: a speaker says that making life-saving insulin makes the proposal obviously ethical, with nothing else to weigh. Explain the flaw using a benefit and a separate safety question.

Return to E1 for the benefit and E3 for what risk assessment must establish. Do not replace the unsupported claim with the opposite claim that every engineered cell causes harm.

If stuck, use M1’s everyday comparison first. Then return to D1, choose a position and list both required reasons. A bakery number cannot supply a bacterial escape rate.

Before the next class, review these conceptual roles. A restriction enzyme cuts DNA at a recognized sequence. A plasmid is a DNA molecule separate from a cell’s main chromosome. [NHGRI-RE] [NHGRI-PLASMID]

A vector carries genetic material in a research context. A selectable marker helps identify a linked feature. [NHGRI-VECTOR] [MARKER] Selection is not itself proof of the intended product or of safe containment.

A positive control is a comparison expected to give the target response. A negative control is expected not to give that response. They help interpret a test; they do not grant safety approval.

Paper example: Card A is described as containing a square; Card B is described as blank. The checker should answer square for A and no square for B. These are stipulated text cases, not a performed test. Decide which card is the positive comparison and which is the negative comparison.

If the blank is called a square, the checker gives a false positive in this model. If the known square is missed, it fails the positive check. Neither result describes bacteria.

Write one question about these roles or comparisons to bring to Monday, May 3. This is concept review only, not permission to run a virtual or physical experiment.

P1: dated work, posting and honest status

For Friday, April 30, save Engineered organism debate in Exit Tickets. Keep the exact one-sentence position with a specific containment or patient-benefit reason, plus the supporting debate and reflection work.

For asynchronous work, draft a 150-word stance, post it on the actual teacher-provided board, then reply to a classmate who took the opposing view.

If the board or opposing post is unavailable, save your draft and complete both C1 solo rounds. Mark the real post and classmate reply pending. Do not count supplied positions as actual classmates.

Nothing new in myPLTW today; catch up on unfinished Problem 5 work. Your teacher may also assign a Problem 6 ethics milestone with a reflection paragraph attachment.

Activity 6.1.1 Restriction Enzyme Challenge may also be assigned. Ask your teacher which work and stopping point apply.

Keep the Problem 5 catch-up duty visible. If a Problem 6 reflection or tracker milestone is assigned, complete its actual requirements before attaching evidence or marking it done.

The original debate is not proof of official activity completion. Keep the reflection paragraph ready, but label any required actual attachment pending until the route is confirmed.

The next scheduled BI lesson is Monday, May 3, Workflow notes and controls. Bring the Q1 question then.

No homework is due before this class. May 6 has its own preparation: Transformation notes, 25 minutes in Class Records. Do not treat this debate as completion of that preparation or a later lab.

If the teacher assigns a molecular workflow plan or virtual cloning task, obtain its actual materials and confirm the required evidence. This debate does not complete either.

The weekly communication product and any actual April 29 submission remain separate. Do not replace today’s task with a different one unless your teacher assigns it.

Use Schoology in your enrolled BI section and match Engineered organism debate by the assignment description. Submit one PDF through the confirmed route and check that the intended file is attached.

Follow teacher name and filename directions locally. If access or the assignment is missing, save the dated work, mark submission pending and ask the teacher for the route.

Actual equipment, course simulations and laboratory materials require their own supplied instructions and approval. Today’s paper discussion authorizes no biological work, medicine production, public release or personal-data collection.

Three examples and one concern

Use all three E1 medicine examples to name the production cell types. Choose one medicine, explain a bounded loss-of-production concern, and name one possible engineering concern.

Use supplied public examples only. A factory can use living cells. No family medication history or global market-share guess is needed.

Position and two reasons

Choose your position on D1. Write one patient-benefit reason and one biosafety reason, each tied to a supplied card and its limit.

Conditional support, waiting or a reasoned objection can be defended. Separate missing information from evidence that harm occurred.

Two debate rounds

Complete both C1 rounds. Track each claim, supporting card, uncertainty and oversight proposal. Reply to the strongest opposing concern.

Use actual group discussion or label the supplied A/B positions and your own responses solo practice. Do not invent participation.

Hardest concern and safeguards reflection

Name the concern hardest to dismiss. Write a reflection paragraph explaining a safeguard, what it addresses, what it cannot prove and what evidence could change your position.

Use E3 and C1. Your paragraph supports today’s work; an actual official reflection attachment remains pending until confirmed.

Benefit is not the whole decision

Answer Q1’s self-check using a patient benefit and a distinct safety question. Explain why a selection marker does not itself establish containment.

Use E1/E2/E3. Do not replace automatic approval with a claim of inevitable harm.

One question for Monday, May 3

Review Q1’s enzyme, plasmid/vector, marker and control roles. Identify the positive and negative comparisons in the paper example, then write one question for next class.

This is conceptual preparation only. No organism, sample, experimental conditions or procedure is needed.

150-word stance and actual opposing-peer reply

For the asynchronous route, write a 150-word stance with both reasons, evidence limits and safeguards. Post and reply to an actual opposing classmate only on the teacher-provided board.

Without the board or post, save the draft, use both C1 solo rounds and mark genuine posting/reply pending. Do not fabricate a classmate response.

Optional strongest opposing argument

Steelman the position you disagree with. Name one piece of evidence that would change your vote and explain why.

Use the matched C1 arguments and D1 limits. No experimental design or real test is requested.

One sentence and actual status

Write exactly one sentence stating whether engineered-organism benefit justifies biosafety risk, with a specific containment or patient-benefit reason. Record actual work and submission status separately.

Keep both preparation reasons and reflection with the sentence. Use P1 for official-work, post/reply, preparation and submission holds.